Gacyclidine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gacyclidine" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

6doi.org

2^nd place

2espacenet.com

800^th place

676^th place

1semanticscholar.org

11^th place

8^th place

doi.org

Stocum DL (2012). "Regenerative Medicine of Neural Tissues". Regenerative Biology and Medicine (Second ed.). pp. 285–323. doi:10.1016/B978-0-12-384860-4.00011-3. ISBN 978-0-12-384860-4.
Chenoweth JA, Gerona RR, Ford JB, Sutter ME, Rose JS, Albertson TE, et al. (March 2015). "Altered mental status and end organ damage associated with the use of gacyclidine: a case series". Journal of Medical Toxicology. 11 (1): 115–120. doi:10.1007/s13181-014-0415-2. PMC 4371039. PMID 25048606.
Hamon J, Espaze F, Vignon J, Kamenka JM (February 1999). "The search for TCP analogues binding to the low affinity PCP receptor sites in the rat cerebellum". European Journal of Medicinal Chemistry. 34 (2): 125–135. doi:10.1016/S0223-5234(99)80046-4.
Maxwell KS, Robinson JM, Hoffmann I, Hou HJ, Searchfield G, Baguley DM, et al. (December 2021). "Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study". Otology & Neurotology. 42 (10). Ovid Technologies (Wolters Kluwer Health): e1625 – e1633. doi:10.1097/mao.0000000000003369. PMC 8584222. PMID 34629442.
Hirbec H, Gaviria M, Vignon J (2001). "Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor". CNS Drug Reviews. 7 (2): 172–198. doi:10.1111/j.1527-3458.2001.tb00194.x. PMC 6741685. PMID 11474423.
Hirbec H, Mausset AL, Kamenka JM, Privat A, Vignon J (May 2002). "Re-evaluation of phencyclidine low-affinity or "non-NMDA" binding sites". Journal of Neuroscience Research. 68 (3): 305–314. doi:10.1002/jnr.10203. PMID 12111860. S2CID 43271240.

espacenet.com

worldwide.espacenet.com

US patent 6107495, Cazaux JB, Dafniet M, Kamenka JM, Manginot E, "Thienylcyclohexane derivatives for thienylcyclohexyl synthesis", issued 22 August 2000, assigned to Ipsen Pharma SAS.
US patent 5179109, Kamenka JM, Privat A, Chicheportiche R, Rondouin G, "Pharmaceutical compositions for neuroprotection containing arylcyclohexylamines", issued 12 January 1993, assigned to Centre National de la Recherche Scientifique CNRS.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chenoweth JA, Gerona RR, Ford JB, Sutter ME, Rose JS, Albertson TE, et al. (March 2015). "Altered mental status and end organ damage associated with the use of gacyclidine: a case series". Journal of Medical Toxicology. 11 (1): 115–120. doi:10.1007/s13181-014-0415-2. PMC 4371039. PMID 25048606.
Maxwell KS, Robinson JM, Hoffmann I, Hou HJ, Searchfield G, Baguley DM, et al. (December 2021). "Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study". Otology & Neurotology. 42 (10). Ovid Technologies (Wolters Kluwer Health): e1625 – e1633. doi:10.1097/mao.0000000000003369. PMC 8584222. PMID 34629442.
Hirbec H, Gaviria M, Vignon J (2001). "Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor". CNS Drug Reviews. 7 (2): 172–198. doi:10.1111/j.1527-3458.2001.tb00194.x. PMC 6741685. PMID 11474423.
Hirbec H, Mausset AL, Kamenka JM, Privat A, Vignon J (May 2002). "Re-evaluation of phencyclidine low-affinity or "non-NMDA" binding sites". Journal of Neuroscience Research. 68 (3): 305–314. doi:10.1002/jnr.10203. PMID 12111860. S2CID 43271240.

ncbi.nlm.nih.gov

Chenoweth JA, Gerona RR, Ford JB, Sutter ME, Rose JS, Albertson TE, et al. (March 2015). "Altered mental status and end organ damage associated with the use of gacyclidine: a case series". Journal of Medical Toxicology. 11 (1): 115–120. doi:10.1007/s13181-014-0415-2. PMC 4371039. PMID 25048606.
Maxwell KS, Robinson JM, Hoffmann I, Hou HJ, Searchfield G, Baguley DM, et al. (December 2021). "Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study". Otology & Neurotology. 42 (10). Ovid Technologies (Wolters Kluwer Health): e1625 – e1633. doi:10.1097/mao.0000000000003369. PMC 8584222. PMID 34629442.
Hirbec H, Gaviria M, Vignon J (2001). "Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor". CNS Drug Reviews. 7 (2): 172–198. doi:10.1111/j.1527-3458.2001.tb00194.x. PMC 6741685. PMID 11474423.

semanticscholar.org

api.semanticscholar.org

Hirbec H, Mausset AL, Kamenka JM, Privat A, Vignon J (May 2002). "Re-evaluation of phencyclidine low-affinity or "non-NMDA" binding sites". Journal of Neuroscience Research. 68 (3): 305–314. doi:10.1002/jnr.10203. PMID 12111860. S2CID 43271240.